PTPN11

PTPN11 encodes SHP-2, a widely expressed non-receptor protein tyrosine phosphatase with a regulatory architecture distinct from receptor phosphatases.¹ The canonical protein contains two tandem Src homology 2 (SH2) domains at its amino terminus, a catalytic protein-tyrosine-phosphatase domain, and a carboxy-terminal tail. In its resting state, the N-terminal SH2 domain folds against the catalytic domain and suppresses enzymatic activity. Binding of phosphorylated signaling proteins relieves this autoinhibition, allowing SHP-2 to act on selected phosphotyrosine substrates.

The gene lies at 12q24.13 and is expressed in many tissues. SHP-2 is not simply an “off switch”: depending on its cellular context, it can remove inhibitory or activating phosphates and thereby promote signaling. Its best-established roles involve receptor tyrosine kinases, cytokine receptors, integrins, and developmental signaling pathways that converge on RAS–MAPK and related networks.¹

PTPN11 helps convert activated surface receptors into regulated intracellular responses. SHP-2 is recruited through its SH2 domains to phosphorylated docking proteins, where its phosphatase activity reshapes complexes containing adaptor proteins and kinases. This supports signaling through the RAS–RAF–MEK–ERK cascade, while also influencing PI3K–AKT, JAK–STAT, and cytoskeletal pathways in particular cellular settings.

The outcome depends on receptor type, substrate availability, developmental stage, and whether SHP-2 activity is increased or reduced. The protein participates in hematopoietic-cell development, skeletal and cardiac development, growth control, and immune signaling. Because it works at signaling junctions rather than as a single linear switch, the same variant can have different effects across tissues. This context dependence also helps explain why inherited and acquired PTPN11 variants produce overlapping but non-identical phenotypes.

Germline PTPN11 variants are a major cause of Noonan syndrome, a developmental disorder that may include characteristic facial features, short stature, congenital heart disease, and variable learning or bleeding abnormalities.² Most disease-associated Noonan variants increase or dysregulate SHP-2 signaling, although their biochemical effects are not uniform. A different set of variants causes Noonan syndrome with multiple lentigines, historically called LEOPARD syndrome; these variants often reduce catalytic activity or alter normal autoinhibition and produce a distinctive pattern involving lentigines, cardiac disease, and other features.³

Somatic, acquired PTPN11 mutations occur in juvenile myelomonocytic leukemia (JMML) and in subsets of acute myeloid leukemia and other malignancies.⁴ In JMML, activating pathway lesions can drive excessive myeloid-cell proliferation and hypersensitivity to granulocyte–macrophage colony-stimulating factor. Genetic interpretation therefore requires distinguishing a constitutional variant, present in all cells, from a tumor-only variant.

PTPN11 illustrates why variant interpretation cannot rely on a simple “more activity equals disease” rule. Closely related variants can cause different syndromes, and some clinically important alleles alter protein regulation without producing a large change in purified phosphatase activity. In Noonan syndrome, the cardiovascular phenotype commonly includes pulmonary valve stenosis, while a smaller group has hypertrophic cardiomyopathy; the distribution varies by molecular mechanism and affected pathway.²

A further nuance is that PTPN11 is both a developmental gene and a cancer gene: the same signaling axis that helps organize embryonic tissues can, when activated in hematopoietic progenitors, support clonal expansion. PTPN11 testing may therefore be relevant to genetic diagnosis, family counseling, tumor profiling, and classification of leukemia-associated mutations. Results are interpreted alongside phenotype, inheritance, allele fraction, tissue source, and established clinical databases rather than from the gene name alone.¹

SHP-2

A cytoplasmic, non-receptor protein tyrosine phosphatase encoded by PTPN11.

SH2 domain

A protein module that recognizes specific phosphorylated tyrosine-containing sequences.

RAS–MAPK pathway

A signaling cascade linking extracellular receptors to gene regulation, proliferation, and differentiation.

Noonan syndrome

A usually autosomal-dominant developmental disorder involving features such as congenital heart disease, short stature, and characteristic facial appearance.

Somatic variant

A genetic alteration acquired during life that is present in some cells but not necessarily inherited or present throughout the body.